Mumbai, July 7 -- Strand Life Sciences, a subsidiary of Reliance Industries Ltd, on Tuesday said it has secured an Indian patent for an integrated platform that uses DNA analysis from a blood sample to detect cancer early, as the country grapples with a growing cancer burden.

The patented platform combines high-quality genome sequencing, rigorous quality control, biologically informed methylation and fragmentomic feature extraction-computational techniques that identify tumour-derived DNA from a simple blood draw-with machine learning. Together, these enable early cancer detection and prediction of the tissue where the cancer originated, the company said.

A key innovation covered by the patent is a method to derive methylation patterns ...